NCT04704661 2026-03-18
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
Phase 1 Recruiting
National Cancer Institute (NCI)
NRG Oncology
National Cancer Institute (NCI)
Fox Chase Cancer Center
University Health Network, Toronto
Duke University